Skip to main content
Figure 1 | The Journal of Headache and Pain

Figure 1

From: Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial

Figure 1

Weekly mean scores as measured by VAS. At baseline, each group was well matched for severity of their VAS scores. After injections, The VAS scores of 25U and 75U groups reduced significantly compared to placebo as early as week 1, and sustained until week 8 throughout the study (*P < 0.017, **P < 0.017) . There was no significant difference between 25U and 75U groups throughout the study (P > 0.05).

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us